Afatinib was initially approved by the U.S. FDA in 2013 for the treatment of advanced NSCLC patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and got a broadened indication as the first‐line treatment of advanced NSCLC patients with nonresistant EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.